AI Hallucinated Citations Are a 110,000-Publication Problem—And a Hidden M&A Due Diligence Gap

A Nature / Grounded AI analysis reveals a contaminated evidence base underneath the SaaS market claims your management team just put in the CIM.DevelopmentCorporate.com  |  April 2026

A computer scientist at the University of Toulouse received a Google Scholar alert earlier this year. One of his papers had been cited in the International Dental Journal. That was strange—his research on fabricated papers doesn’t intersect with dentistry. Stranger still: the citation looked almost like one of his preprints, but the journal was listed as Nature and the DOI pointed nowhere. The citation had been hallucinated by AI.

That incident—documented in a new Nature investigation published April 1, 2026—is not an outlier. It is the leading edge of a documented, measurable contamination of the academic literature. And for PE/VC investors, SaaS founders preparing for exit, and enterprise CTOs evaluating vendor claims, it represents a due diligence gap that current frameworks are not designed to catch.

The Scale of the AI Hallucinated Citations Problem

The Nature analysis—conducted in collaboration with Grounded AI, a citation verification company—analyzed more than 4,000 publications from five major publishers: Elsevier, Sage, Springer Nature, Taylor & Francis, and Wiley. Manual review of the 100 most suspicious papers confirmed 65 contained at least one invalid reference—a citation pointing to a publication that does not exist.

Extrapolated across the roughly 7 million scholarly publications from 2025, that rate implies more than 110,000 publications from last year contain invalid AI-generated references. And that estimate is almost certainly low. The analysis focused on large publishers with more resources for pre-publication checking. Smaller publishers, and fields like computer science where LLM usage in manuscript production has surged, are likely worse.

Figure 1: Hallucinated citation rates jumped 5–10x from 2024 to 2025 across computer science conferences. Sources: Sakai et al. (arXiv 2026); Bienz et al. (arXiv 2026); Nature / Grounded AI (April 2026).

The growth trajectory is the signal. One analysis of 18,000 computer science conference papers found that papers containing at least one potentially hallucinated citation jumped from 0.3% in 2024 to 2.6% in 2025—nearly a 9x increase in a single year. A parallel analysis of four other 2025 CS conferences estimated 2–6% of papers included unverifiable or rephrased citations. A separate study using GPT-4o to generate synthetic literature reviews found that nearly 20% of AI-generated references were fully fabricated, and 45% of the remainder contained errors including invalid DOIs.

The mechanism has a name. Joe Shockman, co-founder and CEO of Grounded AI, calls them “Frankenstein citations”—references assembled from fragments of genuine publications, each component plausible, the composite pointing nowhere. The DOI looks real. The author names are familiar. The journal is credible. Only when you click through does the fabrication reveal itself.

Why This Is an M&A Due Diligence Problem, Not Just a Research Integrity Problem

The academic community is treating this as a publishing crisis. That framing is accurate but incomplete. For practitioners evaluating enterprise SaaS transactions in 2026, AI hallucinated citations represent a specific, underpriced liability class that appears in three distinct deal contexts.

Market Sizing Claims Built on Hallucinated Evidence

SaaS companies routinely cite peer-reviewed research to anchor TAM figures, validate category claims, and support pricing in investor materials. A health tech company might cite a clinical study to support its efficacy narrative. A compliance SaaS vendor might cite a regulatory research paper to establish the market’s urgency. An edtech platform might reference academic learning science to justify its methodology premium.

If the cited research contains hallucinated references—or if AI was used to locate and summarize that research and introduced fabrications in the process—the evidentiary foundation of those claims is compromised. Standard due diligence processes do not check whether the citations in a target’s market research are valid. They treat documents as authoritative unless they contain obvious red flags. A hallucinated citation does not announce itself.

As we documented in our analysis of AI hallucinations in M&A workflows, a Deloitte survey found that 47% of enterprise AI users made at least one major business decision based on hallucinated content. These are not naive users. They are professionals who believe they exercised oversight—and who did not catch what the AI fabricated.

The CIM as a Contamination Vector

The Confidential Information Memorandum is where executive representation risk concentrates. Management teams using AI to draft sections of the CIM—summarize market research, compile customer testimonials, build the competitive landscape narrative—may have unknowingly embedded hallucinated claims into materials a buyer will treat as verified facts.

We have written about this dynamic in detail in our analysis of AI hallucination rates as a due diligence crisis. The vendor benchmark for AI hallucination—sub-1% on short, clean documents—is measured under conditions that bear no resemblance to the multi-source synthesis tasks that produce CIM content. On complex domain-specific queries, observed hallucination rates reach 69–88%.

The Nature analysis adds a specific new dimension to this risk. It is not just that AI hallucinates during document synthesis. It is that the academic literature AI models use as source material is itself now contaminated with hallucinated citations. A model that accurately summarizes a paper that contains fabricated references will faithfully reproduce those fabrications. The error compounds upstream.

Figure 2: Observed hallucination rates across task types vs. the 0.9% vendor benchmark. Sources: Vectara HHEM Leaderboard; Linardon et al. JMIR Mental Health (2025); Stanford RegLab; Nature / Grounded AI (2026).

Product Validation Risk in Health Tech, LegalTech, and Compliance SaaS

The highest-risk acquisition targets are companies whose product value proposition rests on peer-reviewed efficacy evidence. Health tech platforms citing clinical literature. LegalTech vendors referencing judicial outcome studies. Compliance SaaS companies grounding their risk scoring models in regulatory research.

As we documented in our analysis of AI hallucinations in legal filings, courts are now actively sanctioning AI-generated citation errors with penalties exceeding $100,000. The same hallucination dynamic that is contaminating academic literature is producing fabricated citations in legal briefs—and judges are treating the attorney, not the AI, as responsible.

For M&A buyers, the question is straightforward: if the research cited in support of a product’s efficacy claims turns out to contain hallucinated references, what happens to the representations made in the purchase agreement? And who bears the liability when post-close diligence—or a regulator—discovers the evidence base was contaminated?

Implications by Audience

For PE/VC InvestorsAdd citation verification to AI-heavy deal diligence. Any target whose CIM relies on academic research to anchor market sizing should have that research independently verified before closing.Treat “proprietary research” claims skeptically. A target that claims its market position is backed by peer-reviewed evidence should be asked to produce the original papers—and those papers should be checked against authoritative databases.Recognize citation verification as an emerging SaaS investment category. Grounded AI’s Veracity tool—now used by IOP Publishing to screen all submissions—represents a product architecture with natural switching costs and institutional buyers who cannot risk false negatives.

For SaaS Founders Evaluating Exit TimingAudit your CIM’s evidentiary claims before the buyer does. Every academic citation in your market sizing, competitive positioning, or product efficacy narrative should be traceable to a real, accessible publication.If your team used AI to draft or research sections of investor materials, conduct a retroactive hallucination audit. The standard “human review” defense may not hold if the human reviewer trusted the AI’s citations without independent verification.Proactive disclosure of AI use in content creation—with documented verification workflows—is increasingly a trust signal in sophisticated M&A processes. Buyers are starting to ask.

For Enterprise CTOs and CPOsYour vendor evaluation process needs a citation verification layer. Any AI vendor whose product ingests or synthesizes academic literature—research tools, literature review platforms, competitive intelligence systems—should be asked how it validates citations against authoritative databases.The contamination is upstream of your AI system. If the academic papers your AI summarizes contain hallucinated references, your AI will faithfully reproduce those fabrications. The problem is not just your model—it is the training data and source material the model draws on.Build citation auditing into any workflow where AI-generated research informs regulatory submissions, clinical claims, or legal arguments. The standard is shifting: “the AI made a mistake” is not an acceptable defense in courts or in FDA submissions.

A New SaaS Category Is Emerging From the Wreckage

Every documented crisis in enterprise software creates a product category to solve it. The AI citation contamination crisis is no different.

Grounded AI’s Veracity tool—which checks citations against scholarly databases and flags invalid, irrelevant, or retracted references—is now being used by IOP Publishing to screen all journal submissions. Frontiers has built an in-house AI integrity tool that flags reference issues at the point of submission. The company says around 5% of manuscripts show potential reference-related issues. Multiple major publishers told Nature they are exploring similar screening capabilities.

The commercial characteristics of citation verification infrastructure are favorable. Institutional buyers—publishers, law firms, pharmaceutical companies, regulatory affairs teams—have high switching costs and cannot afford false negatives. The product requires proprietary integration with scholarly databases that are themselves gated. And the liability context for errors is escalating, which increases willingness to pay.

Figure 3: Estimated scale of AI citation contamination in 2025 academic literature (log scale). Confirmed invalid references represent only the tip of a much larger undetected population. Sources: Nature / Grounded AI analysis (April 2026).

This mirrors the investment thesis we identified in our analysis of AI hallucination rates in legal SaaS: the same hallucination crisis that creates liability for AI users creates a buying event for tools that solve the verification problem. Investors who recognize citation verification as a distinct, fundable product category—rather than a feature of a larger research platform—will have an early-mover advantage.

What Due Diligence Teams Should Be Asking Right Now

The following questions should be added to standard due diligence frameworks for any transaction where AI use is material to the target’s product or go-to-market positioning.

• Were AI tools used in drafting any investor materials, including the CIM, management presentations, or financial model commentary? If so, what was the verification workflow for academic citations and market data claims?
• Does the target’s product ingest or summarize academic literature? If so, how does the platform validate citations before surfacing them to users?
• Has the target conducted a retroactive audit of AI-generated content in customer-facing materials, regulatory submissions, or product documentation?
• What is the specific hallucination rate for the AI models used, measured on the domain-specific tasks the product actually performs—not on general benchmarks?
• Has R&W insurance underwriting specifically asked about AI hallucination risk, including citation fabrication? If not, proactively address this before the insurance stage.

Our M&A due diligence checklist covers AI hallucination risk assessment in detail. The citation contamination problem identified by Nature and Grounded AI adds a new, specific layer to that framework that did not exist at this scale twelve months ago.

The Gap Thesis, Applied to Academic Evidence

The recurring theme across our AI due diligence research is the gap between claimed performance and verified reality. Vendor benchmarks vs. production hallucination rates. AI productivity narratives vs. audited operational outcomes. Executive representation vs. documented system behavior.

The Nature analysis adds another dimension to that gap thesis. The academic literature that AI models draw on—the evidence base that SaaS companies cite to validate their markets, their products, and their management team’s expertise—is itself now partially contaminated. The citations look real. The DOIs look valid. The journals are credible. And tens of thousands of them point nowhere.

Standard due diligence was not designed to catch this. It needs to be.To discuss how citation verification and AI hallucination risk fit into your current M&A framework, visit DevelopmentCorporate.com or contact us directly.